Report cover image

Colorectal Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Jan 01, 2025
Length 132 Pages
SKU # FOB19554799

Description

Growth Factors of Colorectal Cancer Therapeutics Market

The colorectal cancer therapeutics market size was valued at USD 9.26 billion in 2018, and the market is now projected tgrow from USD 26.49 billion by 2032, exhibiting a CAGR of 7.8% during the forecast period of 2019-2026.

An increase in awareness has brought the colorectal cancer therapeutics market growth at the global level and market players have been launching new products intthe market. However, most medications require a prescription and usually accompany other medications, hence increasing the demand for many separate drugs. Market players are launching high-value drugs tcater tvarious treatment requirements. Market growth is being driven by innovation and patient care features.

People are becoming more informed about the dangerous health effects associated with colorectal cancer, which is capable of spreading. New and more advanced forms of diagnostics are increasing the percentage of early diagnosis, which may increase the number of cases recorded worldwide. When these diseases are diagnosed early enough, treatment yields better results and higher chances of survival. A gradual increase in disease awareness and improvements in diagnostic reach are other beneficial market factors that propel the colorectal cancer therapeutics market share.

Comprehensive Analysis of Colorectal Cancer Therapeutics Market

The colorectal cancer therapeutics market and healthcare industry is rising at an exponential rate due tits market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated by therapy, by cancer type and by distribution channel. The theraphy includes, Targeted Therapy, Immunotherapy, Chemotherapy and Others. The cancer type includes, Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Others. The distribution channel includes, Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies and Others.

North America generated USD 4.13 billion in 2018 for colorectal cancer medications and is expected tdominate the market. Cancer and new products support the industry. The Incidence of high cancers and the introduction of new products support the industry. More research and awareness add tthe market's growth even more. This modern diagnostic technique boosts the region’s extension. These issues make North America a strong market force for the U.S. twin the war even when faced with tough competition from its counterparts.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Genentech, Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Sanofi, Merck Sharp & Dohme Corp., TaihPharmaceutical (Otsuka Pharmaceutical Co., Ltd.), Bayer AG, Regeneron Pharmaceuticals, Inc., Novartis AG and Ipsen Biopharmaceuticals, Inc. These market players provide a level-playing competitive landscape.

In July 2020, TaihPharmaceutical Co., Ltd. started distributing its anticancer agent LONSURF tColorectal Cancer patients in China. The company assumed that Lonsurf would be a more valuable addition tthe patients and medical facilities, as a decision of the patient with colorectal cancer.

Segmentation Table

Global Colorectal Cancer Therapeutics Market Scope

Study Period 2015-2026

Base Year 2018

Forecast Period 2019-2026

Growth Rate CAGR of 7.8% from 2019 t2026

Historical Period 2015-2017

Unit Value (USD billion)

Segmentation By Therapy, Cancer Type, Distribution Channel and Geography

By Therapy

Targeted Therapy

Immunotherapy

Chemotherapy

Others

By Cancer Type

Colorectal Adenocarcinoma

Gastrointestinal Carcinoid Tumors

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)

Latin America (Brazil, Mexico, and the Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Contents

132 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Colorectal Cancer - By Key Countries, 2018
4.2. Pipeline Analysis, Key Players
4.3. Key Industry Developments
4.4. New Product Launches
4.5. Increasing R&D Initiatives in Colorectal Cancer Diagnostics
5. Global Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Therapy
5.2.1. Targeted Therapy
5.2.2. Immunotherapy
5.2.3. Chemotherapy
5.2.4. Others
5.3. Market Analysis, Insights and Forecast – By Cancer Type
5.3.1. Colorectal Adenocarcinoma
5.3.2. Gastrointestinal Carcinoid Tumors
5.3.3. Others
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1. Hospital Pharmacies
5.4.2. Retail Pharmacies
5.4.3. Online Pharmacies
5.4.4. Others
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
6. North America Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Therapy
6.2.1. Targeted Therapy
6.2.2. Immunotherapy
6.2.3. Chemotherapy
6.2.4. Others
6.3. Market Analysis – By Cancer Type
6.3.1. Colorectal Adenocarcinoma
6.3.2. Gastrointestinal Carcinoid Tumors
6.3.3. Others
6.4. Market Analysis – By Distribution Channel
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies
6.4.3. Online Pharmacies
6.4.4. Others
6.5. Market Analysis – By Country
6.5.1. U.S.
6.5.2. Canada
7. Europe Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis – By Therapy
7.2.1. Targeted Therapy
7.2.2. Immunotherapy
7.2.3. Chemotherapy
7.2.4. Others
7.3. Market Analysis – By Cancer Type
7.3.1. Colorectal Adenocarcinoma
7.3.2. Gastrointestinal Carcinoid Tumors
7.3.3. Others
7.4. Market Analysis – By Distribution Channel
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Online Pharmacies
7.4.4. Others
7.5. Market Analysis – By Country/ Sub-Region
7.5.1. U.K.
7.5.2. Germany
7.5.3. France
7.5.4. Spain
7.5.5. Italy
7.5.6. Scandinavia
7.5.7. Rest of Europe
8. Asia Pacific Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis – By Therapy
8.2.1. Targeted Therapy
8.2.2. Immunotherapy
8.2.3. Chemotherapy
8.2.4. Others
8.3. Market Analysis – By Cancer Type
8.3.1. Colorectal Adenocarcinoma
8.3.2. Gastrointestinal Carcinoid Tumors
8.3.3. Others
8.4. Market Analysis – By Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
8.4.4. Others
8.5. Market Analysis – By Country/ Sub-Region
8.5.1. Japan
8.5.2. China
8.5.3. India
8.5.4. Australia
8.5.5. Southeast Asia
8.5.6. Rest of Asia Pacific
9. Latin America Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026
9.1. Key Findings / Summary
9.2. Market Analysis – By Therapy
9.2.1. Targeted Therapy
9.2.2. Immunotherapy
9.2.3. Chemotherapy
9.2.4. Others
9.3. Market Analysis – By Cancer Type
9.3.1. Colorectal Adenocarcinoma
9.3.2. Gastrointestinal Carcinoid Tumors
9.3.3. Others
9.4. Market Analysis – By Distribution Channel
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.4.4. Others
9.5. Market Analysis – By Country/ Sub-Region
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East & Africa Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026
10.1. Key Findings / Summary
10.2. Market Analysis – By Therapy
10.2.1. Targeted Therapy
10.2.2. Immunotherapy
10.2.3. Chemotherapy
10.2.4. Others
10.3. Market Analysis – By Cancer Type
10.3.1. Colorectal Adenocarcinoma
10.3.2. Gastrointestinal Carcinoid Tumors
10.3.3. Others
10.4. Market Analysis – By Distribution Channel
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.4.4. Others
10.5. Market Analysis – By Country/ Sub-Region
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2018)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles
11.5.1. Genentech, Inc.
11.5.1.1. Overview
11.5.1.2. Products & Services
11.5.1.3. SWOT Analysis
11.5.1.4. Recent Developments
11.5.1.5. Strategies
11.5.1.6. Financials
11.5.2. Eli Lilly and Company
11.5.2.1. Overview
11.5.2.2. Products & Services
11.5.2.3. SWOT Analysis
11.5.2.4. Recent Developments
11.5.2.5. Strategies
11.5.2.6. Financials
11.5.3. Pfizer Inc.
11.5.3.1. Overview
11.5.3.2. Products & Services
11.5.3.3. SWOT Analysis
11.5.3.4. Recent Developments
11.5.3.5. Strategies
11.5.3.6. Financials
11.5.4. Sanofi
11.5.4.1. Overview
11.5.4.2. Products & Services
11.5.4.3. SWOT Analysis
11.5.4.4. Recent Developments
11.5.4.5. Strategies
11.5.4.6. Financials
11.5.5. Teva Pharmaceutical Industries Ltd.
11.5.5.1. Overview
11.5.5.2. Products & Services
11.5.5.3. SWOT Analysis
11.5.5.4. Recent Developments
11.5.5.5. Strategies
11.5.5.6. Financials
11.5.6. Bristol Myers Squibb
11.5.6.1. Overview
11.5.6.2. Products & Services
11.5.6.3. SWOT Analysis
11.5.6.4. Recent Developments
11.5.6.5. Strategies
11.5.6.6. Financials
11.5.7. Merck Sharp & Dohme Corp.
11.5.7.1. Overview
11.5.7.2. Products & Services
11.5.7.3. SWOT Analysis
11.5.7.4. Recent Developments
11.5.7.5. Strategies
11.5.7.6. Financials
11.5.8. Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.)
11.5.8.1. Overview
11.5.8.2. Products & Services
11.5.8.3. SWOT Analysis
11.5.8.4. Recent Developments
11.5.8.5. Strategies
11.5.8.6. Financials
11.5.9. Bayer AG
11.5.9.1. Overview
11.5.9.2. Products & Services
11.5.9.3. SWOT Analysis
11.5.9.4. Recent Developments
11.5.9.5. Strategies
11.5.9.6. Financials
11.5.10. Regeneron Pharmaceuticals, Inc.
11.5.10.1. Overview
11.5.10.2. Products & Services
11.5.10.3. SWOT Analysis
11.5.10.4. Recent Developments
11.5.10.5. Strategies
11.5.10.6. Financials
11.5.11. Novartis AG
11.5.11.1. Overview
11.5.11.2. Products & Services
11.5.11.3. SWOT Analysis
11.5.11.4. Recent Developments
11.5.11.5. Strategies
11.5.11.6. Financials
11.5.12. Ipsen Biopharmaceuticals, Inc.
11.5.12.1. Overview
11.5.12.2. Products & Services
11.5.12.3. SWOT Analysis
11.5.12.4. Recent Developments
11.5.12.5. Strategies
11.5.12.6. Financials
12. Appendix
"

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us